Method for treating and/or preventing infections in infants delivered via caesarean section

a technology for infants and caesarean sections, which is applied in the direction of drug compositions, immunological disorders, metabolism disorders, etc., can solve the problems of high content of intestine flora of infants born via caesarean section, risk of pathogenic infection, and rapid colonization of pathogenic bacteria, so as to improve health, prevent infection, and reduce the effect of occurren

Inactive Publication Date: 2009-09-03
NV NUTRICIA
View PDF5 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]Overcoming these deficiencies results in improved health and prevents and / or treats a variety of disorders.
[0013]In a further aspect the present invention can be suitably brought to practice by incorporation of the present active ingredients in a nutritional composition. Such composition can be administered to the infant without posing a heavy burden on the infant delivered via caesarean section.

Problems solved by technology

Additionally it was found that the intestinal flora of infants born via caesarean section has a high content of (undesirable) Escherichia coli 6 weeks after delivery.
These infants are normally delivered in a hospital environment, which is a risk for pathogenic infection due to the occurrence of nosocomial bacteria.
Additionally, the impaired development of a healthy intestinal flora results in faster colonization of pathogenic bacteria compared to a situation where the infants intestinal tract is inoculated by maternal bacteria.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Molecular Characterization of Intestinal Microbiota in Infants Born by Vaginal Delivery vs. Caesarean Delivery

[0075]In the present study the influence of mode of delivery (caesarean delivery versus vaginal delivery) on the intestinal microbial composition at the third day of life by was studied using by PCR amplification with species-specific primers for ten Bifidobacterium species, three Ruminococcus species and one Bacteroides species.

[0076]The microbial DNA was extracted and analysed according to Favier et al, Environ Microbiol 2002; 68:219-226 and Satokari et al, Appl Environ Microbiol 2001; 67:504-513; Satorkari et al System Appl Microbiol 2003; 26:572-584.

[0077]The results of the Bifidobacterium and other species detected in faecal samples of 21 newborns after caesarean delivery obtained at the 3rd day of life are given in Table 1. Table 2 gives the Bifidobacterium and other species detected in faecal samples of 21 newborns after vaginal delivery obtained at the 3rd day of lif...

example 2

Anti-Adherence effect of Uronic Acid Oligosaccharides

[0080]The effects of pectin oligosaccharides (39 mol unsaturated galacturonic acid per 100 mol reducing oligosaccharides in the galacturonic acid molecules; and a degree of methylation of 41%) on enteroinvasive E. coli (EIEC 4608-58) was tested. In an invasion assay with cultured human enterocytes (Caco-2) an anti-infective effect of the pectin derived oligosaccharides was demonstrated on the enteroinvasive E. coli. The results indicate a reduced adherence and invasion: 1 hours post exposure bacterial invasion of E. coli into enterocytes was 49% in the presence of pectin oligosaccharide (compared to 100% in the control). This was most likely due to a decreased adherence of the E. coli to enterocyes (46% compared to control). Results also indicated a reduced extracellular growth of the E. coli in the presence of the pectin oligosaccharides compared to the control.

example 3

Bifidogenic effect of Non-Digestible Oligosaccharides on the Flora in Caesarean Section Delivered Infants

[0081]The bifidobacterial content in the feces was determined. The percentage of the genus Bifidobacterium as a total of total bacteria in the first week was 4.3% in caesarean section delivered infants (n=44) versus 19.8% in vaginally delivered infants (n=28). The percentage E. coli after 6 weeks was 11.8% in the caesarean delivered infants.

[0082]These results indicate the desirability of the administration of the present uronic acid oligosaccharides to infants born via caesarean section.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wt. %aaaaaaaaaa
dry weightaaaaaaaaaa
dry weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides the use of a composition comprising uronic acid oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods for feeding infants delivered via caesarean section.BACKGROUND OF THE INVENTION[0002]Human milk comprises non-digestible oligosaccharides which specifically stimulate the growth of lactic acid producing bacteria, such as species belonging to the genus Bifidobacterium and Lactobacillus and prevent the growth and / or adhesion to the intestinal wall of other (pathogenic) bacteria. Hence, when an infant receives human milk, the infant's intestinal flora develops into a healthy flora rich in lactic acid producing bacteria. The presence of a healthy intestinal flora improves gut barrier maturation and / or gut barrier integrity, stimulates the formation of mucus and inhibits pathogen growth and stimulates the immune system.[0003]WO2005039597 discloses a method for enhancing the immune system and the treatment and / or prevention of immune system related disorders in a mammal, particularly newborns, said method comprising the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/16A61K31/702A61K31/7088A23L11/10A23L29/00A23L29/231A23L29/256A23L33/00A61K35/745A61K35/747
CPCA23C9/1234A61K47/36A23C9/206A23L1/0345A23L1/296A23L1/3014A23L1/308A23V2002/00A23Y2220/85A23Y2300/65A61K31/202A61K31/702A61K31/7068A61K31/7072A61K31/7076A61K31/708A61K31/732A61K31/734A61K35/745A61K35/747A23C9/203A61K35/74A23V2200/32A23V2200/3204A23V2200/3202A23V2200/30A23V2200/324A23V2250/28A61K2300/00A23L33/21A23L29/065A23L33/10A23L33/12A23L33/135A23L33/17A23L33/40A61K31/7016A61K31/7064A23V2400/187A23V2400/513A23V2400/521A23V2400/527A23V2400/529A23V2400/515A23V2400/517A23V2400/519A23V2400/535A23V2400/537A23V2400/531A23V2400/533A23V2400/151A23V2400/125A23V2400/157A23V2400/113A23V2400/143A23V2400/165A23V2400/173A23V2400/175A23V2400/249A23V2400/169A23V2250/284A23V2250/5042A23V2250/5062A23V2250/5114A61K31/716A61K31/733A61K35/742A61K35/744A61K36/064A61P1/00A61P1/12A61P1/14A61P11/02A61P11/06A61P17/00A61P27/02A61P31/04A61P37/02A61P37/08Y02A50/30
Inventor SCHMITT, JOACHIMSTAHL, BERNDKNOL, JAN
Owner NV NUTRICIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap